US Drug Recall Register

Is Norethindrone recalled?

Yes — there is an active recall. 5 ongoing FDA recalls mention Norethindrone (34 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Norethindrone. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed.

Class II · Moderate risk Ongoing

Alyacen 7/7/7

Reason Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class III · Low risk Ongoing

Nortrel 7/7/7

Reason Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Teva Pharmaceuticals USA, Inc NDC 0555-9012-58 D-0322-2024
Class III · Low risk Ongoing

Nortrel

Reason Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Teva Pharmaceuticals USA, Inc NDC 0555-9008-67 D-0321-2024
Class III · Low risk Terminated

Mimvey

Reason Mislabeling

Teva Pharmaceuticals USA NDC 0093-5455-42 D-0522-2022
Class III · Low risk Terminated

Mimvey

Reason Mislabeling

Teva Pharmaceuticals USA NDC 0093-5455-28 D-0521-2022
Class II · Moderate risk Ongoing

Combipatch

Reason Failed Stability Specifications; out of specification for shear.

Noven Pharmaceuticals Inc NDC 68968-0525-2 D-0725-2021
Class II · Moderate risk Ongoing

Combipatch

Reason Failed Stability Specifications; out of specification for shear.

Noven Pharmaceuticals Inc NDC 68968-0514-2 D-0724-2021
Class II · Moderate risk Terminated

Balziva 28 Day

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 0555-9034-58 D-0579-2021
Class II · Moderate risk Terminated

Mibelas 24 Fe

Reason Failed Impurities/Degradation Specifications: Out of specification result observed in related substance test.

Lupin Pharmaceuticals Inc. D-1502-2020
Class II · Moderate risk Terminated

Blisovi Fe 1.5/30

Reason Failed Tablet/Capsule Specifications: Complaints related to crumbling of tablets when popped out of the blister pack.

Lupin Pharmaceuticals Inc. NDC 68180-866-11 D-0638-2020
Class II · Moderate risk Terminated

Kaitlib Fe norethindrone and ethinyl estradiol chewable tablets

Reason Failed Impurities/Degradation Specifications: Kaitlib Fe Tablets has an out of specification result observed in long term stability study.

Lupin Pharmaceuticals Inc. NDC 68180-903-11 D-1565-2019
Class II · Moderate risk Terminated

Ortho-Novum 7/7/7

Reason Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

Janssen Pharmaceuticals, Inc. NDC 50458-178-06 D-0218-2019
Class II · Moderate risk Terminated

Ortho-Novum 1/35

Reason Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

Janssen Pharmaceuticals, Inc. NDC 50458-176-28 D-0217-2019
Class I · High risk Terminated

Mibelas 24 Fe

Reason Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.

Lupin Limited (Unit 1) NDC 68180-911-11 D-1093-2017
Class II · Moderate risk Terminated

Mimvey Lo

Reason Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.

Teva Pharmaceuticals USA NDC 0093-5454-18 D-0479-2017
Class III · Low risk Terminated

Norethindrone Acetate and Ethinyl Estradiol Tablets

Reason Chemical Contamination: out of specification results for impurities were found to be the result of contamination of product from vapors associated with paint thinner used in repair of the manufacturing room.

Mylan Pharmaceuticals Inc. NDC 0378-7280-85 D-0861-2017
Class III · Low risk Terminated

Tarina Fe 1/20

Reason Chemical Contamination: out of specification results for impurities were found to be the result of contamination of product from vapors associated with paint thinner used in repair of the manufacturing room.

Mylan Pharmaceuticals Inc. NDC 50102-128-01 D-0860-2017
Class III · Low risk Completed

Gildess 24 FE 1.5/30

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7610-49 D-0123-2017
Class III · Low risk Completed

Gildess FE 1.5/30

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7608-17 D-0122-2017
Class III · Low risk Completed

Gildess FE 1/20

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7609-17 D-0121-2017
Class III · Low risk Completed

Gildess 1/20

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7607-48 D-0120-2017
Class III · Low risk Completed

Gildess 1.5/30

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7606-48 D-0119-2017
Class II · Moderate risk Terminated

Norethindrone Acetate active pharmaceutical ingredient packaged…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-820-2015
Class III · Low risk Terminated

Camila

Reason Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Teva Pharmaceuticals USA, Inc. NDC 0555-0715-58 D-690-2013
Class III · Low risk Terminated

Errin

Reason Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Teva Pharmaceuticals USA, Inc. NDC 0555-0344-58 D-689-2013